Near Final Height in Males treated with Aromatase Inhibitors

Athanasia Bouliari; Anjile An; Oksana Lekarev; Karen Lin-Su

doi:10.4274/jcrpe.galenos.2025.2025-10-4

January 15, 2026Journal of Clinical Research in Pediatric EndocrinologyOpen Access

Near Final Height in Males treated with Aromatase Inhibitors

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to compare height outcomes of males treated with different aromatase inhibitors.
Comparison of height gain associated with letrozole and anastrozole.
Analysis of treatment timing in relation to puberty stages.
Assessment of the impact of growth hormone therapy duration.
Letrozole treatment showed a greater increase in height than anastrozole.
Younger age at treatment initiation correlated with higher height gains.
Concurrent growth hormone therapy contributed to improved height outcomes.

Implication

Findings show letrozole improves height in males, indicating optimal treatment strategies.

Abstract

Our findings suggest that letrozole is associated with greater gain in height compared to anastrozole in males with ABA. Other factors associated with greater gains are treatment at earlier stages of puberty, longer duration of treatment and concurrent GH therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bouliari et al. (2026) studied this question.

synapsesocial.com/papers/696b2672d2a12237a9349c7b https://doi.org/10.4274/jcrpe.galenos.2025.2025-10-4

View Full Paper

Ask AI

Bookmark

Share

Near Final Height in Males treated with Aromatase Inhibitors

Key Points

Implication

Abstract

Discussion

Cite This Study

Near Final Height in Males treated with Aromatase Inhibitors

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading